Last reviewed · How we verify
SNB-101
At a glance
| Generic name | SNB-101 |
|---|---|
| Also known as | SN-38 |
| Sponsor | SN BioScience |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer (PHASE1, PHASE2)
- Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SNB-101 CI brief — competitive landscape report
- SNB-101 updates RSS · CI watch RSS
- SN BioScience portfolio CI